Insider Trading Alert - SO, FB And ALXN Traded By Insiders
Yesterday, Nov. 4, 2015, 107 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $85.86 to $4,999,847.37.
Highlighted Stocks Traded by Insiders:
Southern (SO) - FREE Research Report
Greene Kimberly S,, who is EVP & COO, Southern Co. at Southern, sold 6,111 shares at $44.84 on Nov. 4, 2015. Following this transaction, the EVP & COO, Southern Co. owned 38,427 shares meaning that the stake was reduced by 13.72% with the 6,111-share transaction.
The shares most recently traded at $45.79, up $0.95, or 2.07% since the insider transaction. Historical insider transactions for Southern go as follows:
- 4-Week # shares bought: 2,000
- 12-Week # shares bought: 2,000
- 24-Week # shares bought: 2,000
The average volume for Southern has been 5.2 million shares per day over the past 30 days. Southern has a market cap of $41.3 billion and is part of the utilities sector and utilities industry. Shares are down 6.74% year-to-date as of the close of trading on Wednesday.
The Southern Company, together with its subsidiaries, operates as a public electric utility company. The stock currently has a dividend yield of 4.78%. The company has a P/E ratio of 20.6. Currently, there is 1 analyst who rates Southern a buy, 2 analysts rate it a sell, and 10 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on SO - FREE
rates Southern as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Facebook (FB) - FREE Research Report
Stretch Colin, who is VP, Gen. Counsel & Secretary at Facebook, sold 1,000 shares at $103.35 on Nov. 4, 2015. Following this transaction, the VP, Gen. Counsel & Secretary owned 77,924 shares meaning that the stake was reduced by 1.27% with the 1,000-share transaction.
The shares most recently traded at $109.03, up $5.68, or 5.21% since the insider transaction. Historical insider transactions for Facebook go as follows:
- 4-Week # shares sold: 53,778
- 12-Week # shares sold: 199,177
- 24-Week # shares sold: 369,103
The average volume for Facebook has been 29.8 million shares per day over the past 30 days. Facebook has a market cap of $231.8 billion and is part of the technology sector and internet industry. Shares are up 33.22% year-to-date as of the close of trading on Wednesday.
Facebook, Inc. operates as a social networking company worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications. The company has a P/E ratio of 104.7. Currently, there are 29 analysts who rate Facebook a buy, no analysts rate it a sell, and 1 rates it a hold.
Exclusive Offer: Get the latest Stock Analysis on FB - FREE
rates Facebook as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Alexion Pharmaceuticals (ALXN) - FREE Research Report
Parven Alvin S, who is Director at Alexion Pharmaceuticals, sold 895 shares at $178.73 on Nov. 4, 2015. Following this transaction, the Director owned 4,645 shares meaning that the stake was reduced by 16.16% with the 895-share transaction.
Islam Saqib, who is EVP, Chief Strat & Port. Off. at Alexion Pharmaceuticals, sold 975 shares at $180.00 on Nov. 4, 2015. Following this transaction, the EVP, Chief Strat & Port. Off. owned 37,335 shares meaning that the stake was reduced by 2.55% with the 975-share transaction.
The shares most recently traded at $171.87, down $8.13, or 4.73% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:
- 4-Week # shares bought: 500
- 4-Week # shares sold: 1,558
- 12-Week # shares bought: 500
- 12-Week # shares sold: 3,688
- 24-Week # shares bought: 500
- 24-Week # shares sold: 37,739
The average volume for Alexion Pharmaceuticals has been 1.8 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $40.2 billion and is part of the health care sector and drugs industry. Shares are down 5.17% year-to-date as of the close of trading on Wednesday.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has a P/E ratio of 157.2. Currently, there are 12 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE
rates Alexion Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full
Alexion Pharmaceuticals Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.